| Predicate | Object |
|---|---|
| rdf:type | |
| biopax3:comment |
Amplified FGFR2 has been shown to be a potential target for a number of ATP-competitive inhibitors, some of which are currently in clinical trials for therapeutic use (Takeda, 2007; Turner, 2010; http://clinicaltrials.gov).
|
| biopax3:xref | |
| biopax3:evidenceCode |